A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab

Abstract Since the beginning of the pandemic, numerous national and international clinical trials have been conducted with a large number of drugs. Many of them are intended for the treatment of other pathologies; however, despite the great effort made, no specific drug is available for the treatment of the symptoms of respiratory disease caused by SARS-CoV-2 infection. The aim of this article is to provide data to justify the use of drugs to tackle the effects produced by IL-6 as the main inflammatory mediator in patients with COVID-19 with severe respiratory complications, considering all clinical evidence linking the poor prognosis of these patients with increased IL-6 levels in the context of cytokine release syndrome. Furthermore, data are provided to justify the proposal of a rational dosing of siltuximab, a monoclonal antibody specifically targeting IL-6, based on RCP levels, considering the limited results published so far on the use of this drug in COVID-19. A literature search was conducted on the clinical trials of siltuximab published to date as well as on the different IL-6 signalling pathways and the effects of its overexpression. Knowledge of the mechanisms of action on these pathways may provide important information for the design of drugs useful in the treatment of these patients. This article describes the characteristics, properties, mechanism of action, therapeutic uses and clinical studies conducted with siltuximab so far. The results confirm that administration of siltuximab downregulates IL-6 levels, thereby reducing the inflammatory process in COVID-19 patients with severe respiratory disease, suggesting that it can be successfully used to prevent cytokine release syndrome and death from this cause..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:39

Enthalten in:

Advances in therapy - 39(2022), 3 vom: 24. Jan., Seite 1126-1148

Sprache:

Englisch

Beteiligte Personen:

Villaescusa, Lucinda [VerfasserIn]
Zaragozá, Francisco [VerfasserIn]
Gayo-Abeleira, Irene [VerfasserIn]
Zaragozá, Cristina [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

COVID-19
Cytokine release syndrome
Interleukin-6
Monoclonal antibodies
Siltuximab

Anmerkungen:

© The Author(s) 2022

doi:

10.1007/s12325-022-02042-3

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2129737226

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?